Aethlon Medical Inc
NASDAQ:AEMD
Aethlon Medical Inc
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The firm operates through two segments: Aethlon and ESI. The Aethlon segment represents its therapeutic business activities. The ESI segment represents its diagnostic business activities. The firm's product, Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The Aethlon Hemopurifie is designed for the single-use removal of exosomes and life-threatening viruses from the human circulatory system. In cancer, the Aethlon Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis. The Company, through its subsidiary Exosome Sciences, Inc. (ESI) is developing exosome-based biomarkers in patients with, or at risk for, a number of cancers.
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The firm operates through two segments: Aethlon and ESI. The Aethlon segment represents its therapeutic business activities. The ESI segment represents its diagnostic business activities. The firm's product, Aethlon Hemopurifier is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The Aethlon Hemopurifie is designed for the single-use removal of exosomes and life-threatening viruses from the human circulatory system. In cancer, the Aethlon Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis. The Company, through its subsidiary Exosome Sciences, Inc. (ESI) is developing exosome-based biomarkers in patients with, or at risk for, a number of cancers.
Cost Reductions: Operating expenses dropped by 48% year-over-year, reflecting lower payroll, fewer bonuses, and reduced trial and admin costs.
Cash Position: The company ended the quarter with about $5.8 million in cash.
Clinical Progress: The Australian oncology trial completed Cohort 1 with no serious safety issues and is moving to Cohort 2, though enrollment is slow.
Trial Results: Early data showed decreases in targeted cancer markers (EVs and certain T cells) after Hemopurifier treatment, but more patients are needed for confidence.
Long COVID Research: Preclinical data on Hemopurifier for Long COVID presented at a major symposium, with plans for a publication soon.
Enrollment Efforts: New digital recruitment and site expansion steps are underway to accelerate trial enrollment, aiming for roughly one patient per month in Cohort 2.
Strategic Focus: Management is prioritizing core oncology and Long COVID programs due to limited resources, with possible future expansion if funding allows.
